XGN · Exagen Inc.
$6.65
+0.20 (+3.10%)
At close · Aug 5
Market Cap
$113.07M
Shares
24.23M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.65
Open$6.58
Day$6.39–7.10
52W$2.59–12.23
Avg vol 30d336K
Short int979K · 4.0% float · 4.5d
Short vol11%
Last earningsAug 4, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.46
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+28%
above
Price vs 50-day avg
+43%
above
RSI (14)
75
overbought
MACD trend
Positive
52-week position
42%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+53%
trailing
6-month return
+102%
trailing
YTD return
+9%
this year
Relative strength
+90%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
7 of 61 funds reported for Jun 30 · net +158.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.04% of float · ▲ +20.4% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
61 holders — mid 3-yr range
Squeeze score
91
high risk · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
Gross margin
58%
contracting
EPS growth
−12%
Y/Y
Free cash flow
$-14.3M
Balance sheet
$9.3M
net cash
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Revenue
· full-year 2026
Raised
$72M – $75M
prior FY $66.58M
midpoint +10.4% Y/Y
Guided vs delivered
· last 1 settled
Revenue
full year
guided $65M – $70M
$66.58M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+28%
Bullish
Price vs 50-day avg
+43%
Bullish
RSI (14)
75
Bearish
MACD trend
Positive
Bullish
52-week position
42%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
7 of 61 funds reported for Jun 30 · net +158.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.04% of float · ▲ +20.4% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
61 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3
Now $7 · 42%
52-wk high $12
vs 200-day avg +28%
vs 50-day avg +43%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -2,274K | Six Months Ended June 30, 2026 | — |
|
|
|||
| Trailing-twelve-month average selling price (ASP) | $446 | Q2 2026 | — |
|
|
|||
| AVISE CTD test volume growth | 10% | Q1 2026 | — |
| patients tested by AVISE CTD | 137,000 | Year Ended December 31, 2025 | — |
| Year-end cash and cash equivalents | $32M | Twelve Months Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XGN
this stock
Exagen Inc.
|
$113.07M | +9.4% | +5.9% | — | 4.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$212.25B | -0.1% | +0.4% | 30.9 | 1.4% |
|
DHR
Danaher Corp /De/
|
$140.36B | -12.4% | +8.5% | 35.4 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$46.07B | -13.6% | +10.4% | 41.1 | 2.7% |
|
A
Agilent Technologies, Inc.
|
$39.85B | +4.3% | +6.4% | 28.3 | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XGN | +52.9% | +52.5% | +101.5% | +46.8% | +9.4% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | +47.3% | +49.3% | +90.3% | +43.8% | -3.5% |